Sutent sunitinib: Preliminary Phase III data

Top-line data from the double-blind, international Phase III SUN 1087 trial in about 956 NSCLC patients previously treated with a platinum-based chemotherapy regimen showed that 37.5 mg/day oral Sutent plus 150 mg/day Tarceva erlotinib missed the primary endpoint of significantly improving OS vs. placebo plus Tarceva. Sutent plus Tarceva did meet the secondary endpoint of significantly improving PFS vs. placebo plus Tarceva. There were no new or unexpected adverse events observed. Pfizer said it will analyze the data from the trial to determine whether it can identify subgroups of NSCLC patients for a future trial. Data were submitted for presentation at the European Society for Medical Oncology meeting in Milan in October. ...